
The FDA’s Oncologic Drugs Advisory Committee voted in favor of the agency approving pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor – a rare, benign lesion that can be locally aggressive and often recurring.
The FDA’s Oncologic Drugs Advisory Committee voted in favor of the agency approving pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor – a rare, benign lesion that can be locally aggressive and often recurring.
The New York City chef dreamed of opening her own restaurant.
The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for three indications.
Nicholas J. Vogelzang, M.D., FASCO, FACP, has seen cancer through a variety of lenses – from oncologist to patient as well as caregiver – giving him a different perspective than most.
Research continues to drive the oncology field.
New clinical trials have oncologists excited about potential new therapies for patients.
Professional snowboarder Bibian Mentel-Spee inspires through her perseverance despite facing multiple bouts with the disease.
Recovery from cancer doesn’t just involve physical health; it often involves overcoming the financial barriers between illness and wellness that make moving forward seem impossible.
Do I really have to wear a prosthesis?
Finding out you have an illness is quite difficult.
Fighting retroperitoneal sarcoma can be like fighting a rare and giant beast.
Cancer not only affects the body, it affects the mind as well.
There are many ways to celebrate the absence of cancer.
Michaela Mueller, event manager at the Sarcoma Foundation of America, discusses the importance of seeing a doctor who specializes in sarcoma.
Many survivors of Ewing sarcoma have few complications and long-term side effects later on, according to a recent study.
John E. Mullinax, M.D., discusses a chemotherapy strategy that may be able to save the limbs of some patients with sarcoma.
A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma.
Patients with certain types of sarcoma may benefit from PD-1 blockades, according to a recent study.
Dimosthenis Andreou, M.D., discussed the Euro-EWING99 trial with CURE.
Immunotherapy's role for treating sarcoma is being cemented as more agents and targets are identified.
Treatment and imaging advancements are drastically changing the landscape of sarcoma care.
A Lartruvo (olaratumab) combination received an accelerated approval from the FDA to treat patients with soft tissue sarcoma.
A recent trial presented an unexpected survival benefit for patients with high-risk soft tissue sarcoma who were on anthracycline-based neoadjuvant chemotherapy.
Immunotherapy may not end up being as successful in treating sarcoma as it is in other types of cancer, says Katherine Thornton M.D.